NEKTAR THERAPEUTICS
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA, 94158
Mailing Address
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA, 94158
Phone
4154825300
Fiscal Year End
1231
EIN
943134940
Financial Overview
FY2025
-$118.96M
Net Income
$303.85M
Total Assets
$243.11M
Total Liabilities
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | March 27, 2026 | View on SEC |
| 10-K Annual financial report | March 13, 2026 | View on SEC |
| 8-K Current report of material events | March 12, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | March 6, 2026 | View on SEC |
| 4 Insider stock transaction report | February 20, 2026 | View on SEC |
| 4 Insider stock transaction report | February 20, 2026 | View on SEC |
| 424B5 Prospectus supplement | February 13, 2026 | View on SEC |
| 8-K Current report of material events | February 13, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 13, 2026 | View on SEC |
| 8-K Current report of material events | February 10, 2026 | View on SEC |
Annual Reports
10-K
March 13, 2026
- Advancing Rezpegaldesleukin (Rezpeg) with initial data readouts anticipated in late 2026 for autoimmune conditions.
- Achieved significant annualized cost savings of $40 million and streamlined operations through restructuring.
Insider Trading
SELL
3 insiders
6 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.